<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1082">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715607</url>
  </required_header>
  <id_info>
    <org_study_id>2021-01</org_study_id>
    <nct_id>NCT04715607</nct_id>
  </id_info>
  <brief_title>COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens</brief_title>
  <official_title>Comparison of Detection Rate of SARS-CoV-2 in Saliva, Oropharyngeal and Nasopharyngeal Specimens in a Public COVID-19 Test Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Hovedstaden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the SARS-CoV-2 detection rate using either a Saliva,&#xD;
      oropharyngeal swabs or nasopharyngeal swab method for specimen collection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The reference test to evaluate patients with suspected respiratory infection caused by virus&#xD;
      is a real-time reverse transcription-polymerase chain reaction (RT-PCR) from a nasopharyngeal&#xD;
      swab (NPS). However, other specimen collection methods like oropharyngeal swabs (OPS) and a&#xD;
      saliva specimen collection have also been accepted by the Centers for Disease Control and&#xD;
      Prevention for SARS-CoV-2 testing during the current coronavirus disease 19 (COVID-19)&#xD;
      pandemic. It is unclear how much the SARS-CoV-2 detection rate differs when using different&#xD;
      sampling methods and the aim of this study is to compare the expected COVID-19 detection rate&#xD;
      using saliva, oropharyngeal swabs or nasopharyngeal swab in a public setting.&#xD;
&#xD;
      We, therefore, aim to investigate the detection rate of SARS-CoV-2 in Saliva, oropharyngeal&#xD;
      swab, and nasopharyngeal swab specimen samples collected in symptomatic and non-symptomatic&#xD;
      individuals tested for COVID-19 in a public test center during the COVID-19 pandemic.&#xD;
&#xD;
      Individuals referred for outpatient COVID-19 testing center will be invited to participate in&#xD;
      a prospective clinical study. They will have saliva, OPS, and NPS specimen collection&#xD;
      performed at the same time and analyzed separately for SARS-CoV-2. The rate for SARS-CoV-2&#xD;
      detection in saliva, OPS, and NPS will be compared using a logistic regression mixed-effect&#xD;
      analysis. A Sample Size Calculation estimated that a sample of 18,000 participants would be&#xD;
      needed for the trial with 80% power at a significance level of 5%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 22, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants will have Saliva collected and recieve nasopharyngeal swabs and oropharyngeal swabs for SARS-COV2. To avoid systematic bias we plan to randomize the sequence of testing.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 detection rates for oropharyngeal swabs (OPS) compared with nasopharyngeal swabs and saliva collection.</measure>
    <time_frame>48 hours after testing</time_frame>
    <description>Due to the high specificity of RT-PCR, we will define a participant with an RT-PCR positive result from either Saliva, OPS or NPS as having a COVID-19 infection. The combined Saliva/OPS/NPS result will therefore be used as the diagnostic reference standard to calculate the sensitivity for the Saliva, OPS and NPS tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 RT-PCR cycle threshold (Ct) values</measure>
    <time_frame>48 hours after testing</time_frame>
    <description>Ct values are compared between testing methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OPS, NPS and saliva test discomfort and likelihood to get retested</measure>
    <time_frame>immediately after testing (10 minutes)</time_frame>
    <description>Discomfort scores (1-10) and likelihood to get retested are compared between testing methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of mutations in SARS-CoV-2</measure>
    <time_frame>48 hours after testing</time_frame>
    <description>Detection rate of any mutations in SARS-CoV-2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">22000</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>Covid19</condition>
  <condition>Coronavirus</condition>
  <arm_group>
    <arm_group_label>Nasopharyngeal swab, oropharyngeal swab, and salvia collection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will first be tested with nasopharyngeal swabs followed by oropharyngeal swab and saliva collection.&#xD;
The collection material, virus transport medium and laboratory equipment for each method is the same in both arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oropharyngeal swab, salvia collection, and nasopharyngeal swab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will first be tested with oropharyngeal swabs followed by saliva collection and nasopharyngeal swab.&#xD;
The collection material, virus transport medium and laboratory equipment for each method is the same in both arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvia collection, nasopharyngeal swab, and oropharyngeal swab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will first be tested with saliva collection followed by nasopharyngeal swab and oropharyngeal swabs.&#xD;
The collection material, virus transport medium and laboratory equipment for each method is the same in both arms</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sequence of testing.</intervention_name>
    <description>The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.</description>
    <arm_group_label>Nasopharyngeal swab, oropharyngeal swab, and salvia collection</arm_group_label>
    <arm_group_label>Oropharyngeal swab, salvia collection, and nasopharyngeal swab</arm_group_label>
    <arm_group_label>Salvia collection, nasopharyngeal swab, and oropharyngeal swab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  volunteers, who are attending the COVID-19 test facilities to obtain a RT-PCR test.&#xD;
&#xD;
          -  oral and written informed consent to participate before entering the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to understand and provide informed consent.&#xD;
&#xD;
          -  Neck breathers (tracheostomy/laryngectomy patients) or other nasopharyngeal or&#xD;
             oropharyngeal anomalies that do not allow for sampling using swabs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Todsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolai Kirkby, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Clinical Microbiology, Rigshospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Todsen, MD, PhD</last_name>
    <phone>00 45 3545 6033</phone>
    <email>Tobias.todsen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Valby COVID-19 teststed</name>
      <address>
        <city>Copenhagen</city>
        <state>Valby</state>
        <zip>2500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Gredal</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Tobias Todsen</investigator_full_name>
    <investigator_title>MD, PhD, Assistant professor Tobias Todsen</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

